Dr. Ofotokun is a creative clinician-scientist whose career is devoted to caring for individuals living with HIV and to combating the long-term sequelae of HIV among vulnerable populations. His research program has focused on the threat that age-related comorbidities pose to healthy aging in persons with HIV and the disproportionate burden in women. Adopting a clinical and translational research approach, he leads an innovative global research collaboration to understand the pathobiology of these phenomena and has demonstrated that age-related comorbidities may be driven by disruption in the organ-immune interphase (an amenable target); the higher burden in women may relate to synergy between gonadal impairment and chronic inflammation. He was a leading member of the seminal and pivotal ACTG 5257 trial that contributed to the 2015 revision of the US HIV treatment guidelines to prioritize a drug class that is better tolerated by women, a class now recommended globally for first-line treatment by the World Health Organization.